Description

Simple

A chemical used in various types of medications to help pass stool and prepare the intestine for medical tests like colonoscopies.

Clinical

A laxative used to treat constipation and used for bowel preparation before colonoscopies and other procedures.

Overview

Polyethylene glycol is a polyether compound used for many purposes ranging from industrial manufacturing processes to medicine. PEG is the basis of a number of laxatives (e.g., macrogol-containing products, such as Movicol and polyethylene glycol 3350, or SoftLax, MiraLAX,ClearLAX, Osmolax or GlycoLax). Irrigation of the bowel with polyethylene glycol and electrolytes is included in bowel preparation therapy, normally indicated before a colonoscopy to ensure adequate visualization of the bowel. Therapeutic classification is as an Osmotic Laxative that works by drawing water into the lumen of the intestinal tract. Shown to decrease consistency and increase weight of stool in constipated patients at low doses.

Pharmacology

Indication

Used to treat and prevent constipation.

Pharmacodynamic

The pharmacological rationale for the use of polyethylene glycol (PEG) in gastroenterology is its inverse relation between molecular mass and intestinal absorbability, with practically no intestinal absorption at molecular masses exceeding 3000, its lack of intestinal enzymatic degradation or bacter... Read more

Mechanism of action

Polyethylene glycol functions as an osmotic agent, causing excess water to be retained in the stool, stimulating a bowel movement.

Absorption

Usually the high and intermediate molecular weight polyethylene glycol are poorly absorbed after oral administration.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Oral LD50 is > 50 gm/Kg in mice, rats, and rabbits.
In the event of overdosage, diarrhea would be the expected major event. Massive ingestion, prolonged IV infusion, and prolonged application of low weight PEG products have been associated with metabolic acidosis and renal injury. Hypercalcemia co... Read more

Adverse Effects

Contraindications

  • Route:
    • Oral
    • Nasogastric
  • Regions: US
  • Patient Conditions:
      • Name: Ileus
      • Drugbank Id: DBCOND0010794
  • Route:
    • Oral
    • Nasogastric
  • Regions: US
  • Patient Conditions:
      • Name: Toxic colitis
      • Drugbank Id: DBCOND0108606
  • Route:
    • Oral
    • Nasogastric
  • Regions: US
  • Patient Conditions:
      • Name: Toxic megacolon
      • Drugbank Id: DBCOND0096768
  • Route:
    • Oral
    • Nasogastric
  • Regions: US
  • Patient Conditions:
      • Name: Gastrointestinal obstruction
      • Drugbank Id: DBCOND0010786
  • Route:
    • Oral
    • Nasogastric
  • Regions: US
  • Patient Conditions:
      • Name: Bowel Perforation
      • Drugbank Id: DBCOND0062437
  • Route:
    • Oral
    • Nasogastric
  • Regions: US
  • Patient Conditions:
      • Name: Gastric Retention
      • Drugbank Id: DBCOND0088112

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Polyethylene glycol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Polyethylene glycol.
Abicipar Pegol
The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol.
Acebutolol
The serum concentration of Acebutolol can be increased when it is combined with Polyethylene glycol.
Acetaminophen
The serum concentration of Acetaminophen can be increased when it is combined with Polyethylene glycol.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Polyethylene glycol.
Acetyldigoxin
The serum concentration of Acetyldigoxin can be decreased when it is combined with Polyethylene glycol.
Acetylsalicylic acid
The serum concentration of Acetylsalicylic acid can be increased when it is combined with Polyethylene glycol.
Aclidinium
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aclidinium.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Polyethylene glycol.
Agmatine
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Agmatine.
Alcuronium
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alcuronium.
Aldosterone
The serum concentration of Aldosterone can be increased when it is combined with Polyethylene glycol.
Alfentanil
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alfentanil.
Alitretinoin
The serum concentration of Alitretinoin can be increased when it is combined with Polyethylene glycol.
Alloin
The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Alloin.
Almasilate
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Almasilate.
Aloglutamol
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aloglutamol.
Alpelisib
The serum concentration of Alpelisib can be increased when it is combined with Polyethylene glycol.
Alphacetylmethadol
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alphacetylmethadol.
Alphaprodine
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alphaprodine.
7 References
  1. 1 . Hammer HF, Hammer J, Gasche C: [Polyethylene glycol (Macrogol)--an overview of its use in diagnosis and therapy of gastrointestinal diseases]. Wien Klin Wochenschr. 2000 Jan 28;112(2):53-60.PubMed: 10703152
  2. 2 . Muller-Lissner S: Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):391-401. doi: 10.1517/17425255.2013.773972. Epub 2013 Feb 21.PubMed: 23425050
  3. 3 . PLENVU (polyethylene glycol 3350, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) US FDA 2018 Label Link
  4. 4 . PegaLAX (polyethylene glycol 3350) 2017 Canadian Prescribing Information Link
  5. 5 . NIH US National Library of Medicine MedlinePlus: Polyethylene Glycol 3350 Profile Link
  6. 6 . Electronic Medicines Compendium: PegLax (Macrogol 4000) Monograph Link
  7. 7 . NCBI StatPearls [Internet]: Bowel Preparation Link